The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

North America held the largest erythropoietin EPO market share, and Middle East was the fastest-growing region in 2022.

The global erythropoietin EPO market is expected to grow from $13.94 billion in 2022 to $15.52 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The erythropoietin market is expected to grow from $24.2 billion in 2027 at a CAGR of 11.7%.

Major Driver In The Erythropoietin EPO Market ­– Rise In The Incidence Of Chronic Kidney Diseases
For example, according to the Centres for Disease Control and Prevention’s report on chronic kidney disease in the United States published in March 2021, 15% of adults in the United States, or 37 million people, were expected to have chronic kidney disease (CKD) in March 2021. People 65 and older are more likely to develop CKD (38%), followed by those 45-64 (13%), and 18-44 (7%). Chronic kidney disorders cause anaemia, which boosts the need for erythropoietin to treat the illness, driving the market’s revenue.

View More On The Erythropoietin EPO Market Report 2023 – https://www.thebusinessresearchcompany.com/report/erythropoietins-global-market-report

Key Erythropoietin EPO Market Segments
1) By Product: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Other Products
2) By Application: Cancer, Hematology, Renal diseases, Neurology, Other Applications
3) By Drug Class: Biologis, Biosimilar

Recent Erythropoietin EPO Market Trend – Increasing Prevalence Of Kidney Diseases
Erythropoietin is commonly used to treat anaemia in patients with chronic renal disease and is utilised by dialysis patients. According to the American Journal of Kidney Diseases, the proportion of US individuals aged 30 and older with chronic kidney disease (CKD) is expected to rise from 13.2% in 2015 to 16.7% in 2030, an almost 27% increase.  According to Fresenius Medical Care, a German healthcare business, the number of persons suffering from chronic renal failure is predicted to rise from 3.7 million in 2020 to 4.9 million by 2025.  As a result, the increasing prevalence of renal illnesses is likely to drive the erythropoietin market.

Erythropoietin EPO Market Prominent Players
Major players in the erythropoietin EPO market are Amgen Inc., Johnson & Johnson, Roche Group, Pfizer Inc., Novartis, Celltrion Inc., and LG Life Sciences Ltd.

Request A Sample Of The Global Erythropoietin EPO Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3436&type=smp

The Erythropoietin EPO Global Market Report 2023  provides a comprehensive overview on the erythropoietin EPO market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the erythropoietin EPO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Erythropoietin (EPO) is a glycoprotein hormone generated by the kidney’s peritubular cells that spontaneously encourages the production of red blood cells. It is used to treat anaemia, or a lack of red blood cells. Anaemia is characterised by fatigue, tiredness, and shortness of breath because red blood cells transport oxygen to the tissues and organs.

View More Related Reports –
Therapeutic Proteins Global Market Report 2023
Biosimilars Global Market Report 2023
Psoriasis Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model